DANAHER CORP (DHR) Stock Overview
USA - NYSE:DHR - US2358511028 - Common Stock
DHR Key Statistics, Chart & Performance
The current stock price of DHR is 222.73 USD. In the past month the price increased by 22.74%. In the past year, price decreased by -9.23%.
DHR Latest News, Press Relases and Analysis
DHR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.53 | 215.96B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 147.87 | 48.23B | ||
| A | AGILENT TECHNOLOGIES INC | 27.06 | 41.80B | ||
| IQV | IQVIA HOLDINGS INC | 19.17 | 37.38B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.15 | 29.62B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 43.46 | 22.09B | ||
| WAT | WATERS CORP | 29.08 | 21.17B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.72 | 16.76B | ||
| ILMN | ILLUMINA INC | 24.03 | 15.37B | ||
| TEM | TEMPUS AI INC | N/A | 15.12B | ||
| ICLR | ICON PLC | 13.65 | 14.00B | ||
| RVTY | REVVITY INC | 19.95 | 11.32B |
Related stock screener links
About DHR
Company Profile
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 61,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Company Info
DANAHER CORP
2200 Pennsylvania Ave NW Ste 800W
WASHINGTON WASHINGTON DC 20037 US
CEO: Rainer M. Blair
Employees: 62000
Phone: 12028280850
DANAHER CORP / DHR FAQ
What does DHR do?
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 61,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Can you provide the latest stock price for DANAHER CORP?
The current stock price of DHR is 222.73 USD. The price increased by 2.12% in the last trading session.
Does DHR stock pay dividends?
DANAHER CORP (DHR) has a dividend yield of 0.59%. The yearly dividend amount is currently 1.05.
What is the ChartMill technical and fundamental rating of DHR stock?
DHR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the ex-dividend date for DHR stock?
The next ex-dividend date for DANAHER CORP (DHR) is September 26, 2025.
What is the expected growth for DHR stock?
The Revenue of DANAHER CORP (DHR) is expected to grow by 3.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for DANAHER CORP?
DANAHER CORP (DHR) will report earnings on 2026-01-27, after the market close.
DHR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to DHR. When comparing the yearly performance of all stocks, DHR is a bad performer in the overall market: 65.71% of all stocks are doing better.
DHR Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to DHR. While DHR belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
DHR Financial Highlights
Over the last trailing twelve months DHR reported a non-GAAP Earnings per Share(EPS) of 7.71. The EPS increased by 3.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.43% | ||
| ROA | 4.38% | ||
| ROE | 6.86% | ||
| Debt/Equity | 0.33 |
DHR Forecast & Estimates
29 analysts have analysed DHR and the average price target is 246.54 USD. This implies a price increase of 10.69% is expected in the next year compared to the current price of 222.73.
For the next year, analysts expect an EPS growth of 4.87% and a revenue growth 3.84% for DHR